Insider Transactions in Q2 2024 at Hca Healthcare, Inc. (HCA)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,861
-20.18%
|
$921,242
$322.86 P/Share
|
|
May 17
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,725
+15.1%
|
$552,825
$117.35 P/Share
|
|
May 16
2024
|
Kathleen M Whalen SVP & Chief Ethics Officer |
SELL
Open market or private sale
|
Direct |
3,204
-25.31%
|
$1,044,504
$326.3 P/Share
|
|
May 15
2024
|
Jon M Foster EVP and COO |
BUY
Bona fide gift
|
Indirect |
5,350
+8.97%
|
-
|
|
May 15
2024
|
Jon M Foster EVP and COO |
SELL
Bona fide gift
|
Indirect |
5,350
-100.0%
|
-
|
|
May 15
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
1,863
-8.68%
|
$607,338
$326.18 P/Share
|
|
May 15
2024
|
Jon M Foster EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,258
-34.68%
|
$6,930,108
$326.96 P/Share
|
|
May 15
2024
|
Jon M Foster EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
39,465
+28.56%
|
$2,959,875
$75.77 P/Share
|
|
May 15
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,908
-42.57%
|
$3,230,008
$326.96 P/Share
|
|
May 15
2024
|
Joseph A Sowell Iii SVP; Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+44.94%
|
$1,292,000
$68.96 P/Share
|
|
May 09
2024
|
Erol R Akdamar Group President |
BUY
Bona fide gift
|
Indirect |
5,139
+7.83%
|
-
|
|
May 09
2024
|
Erol R Akdamar Group President |
SELL
Bona fide gift
|
Direct |
5,139
-100.0%
|
-
|
|
May 09
2024
|
Jeffrey E. Cohen SVP-Government Relations |
SELL
Open market or private sale
|
Direct |
1,650
-24.14%
|
$516,450
$313.0 P/Share
|
|
May 09
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
6,311
-17.56%
|
$1,994,276
$316.88 P/Share
|
|
May 08
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Bona fide gift
|
Direct |
4,500
-11.13%
|
-
|
|
May 07
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,349
-23.4%
|
$3,877,586
$314.45 P/Share
|
|
May 07
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,660
+26.12%
|
$2,593,740
$139.06 P/Share
|
|
May 06
2024
|
Michael S. Cuffe EVP and Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
1,600
-4.48%
|
$494,400
$309.0 P/Share
|
|
May 03
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
890
-3.98%
|
$277,680
$312.0 P/Share
|
|
May 02
2024
|
Kathryn A. Torres SVP-Payer Contracting & Align. |
SELL
Open market or private sale
|
Direct |
973
-4.17%
|
$303,576
$312.0 P/Share
|
|
May 01
2024
|
Mike A Marks EVP and CFO |
SELL
Bona fide gift
|
Direct |
566
-20.19%
|
-
|
|
Apr 29
2024
|
Thomas F Frist Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,284
+8.69%
|
-
|
|
Apr 29
2024
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
610
+2.86%
|
-
|
|
Apr 29
2024
|
Hugh F Johnston Director |
BUY
Grant, award, or other acquisition
|
Direct |
610
+18.77%
|
-
|
|
Apr 29
2024
|
Michael W Michelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,091
+9.43%
|
-
|
|
Apr 29
2024
|
Wayne Joseph Riley Director |
BUY
Grant, award, or other acquisition
|
Direct |
610
+4.21%
|
-
|
|
Apr 29
2024
|
Andrea B Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
610
+14.8%
|
-
|
|
Apr 29
2024
|
William R Frist Director |
BUY
Grant, award, or other acquisition
|
Direct |
963
+7.48%
|
-
|
|
Apr 29
2024
|
Meg Crofton Director |
BUY
Grant, award, or other acquisition
|
Direct |
610
+8.79%
|
-
|
|
Apr 29
2024
|
Robert J Dennis Director |
BUY
Grant, award, or other acquisition
|
Direct |
963
+3.63%
|
-
|